Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer

Annals of Internal Medicine

Volumn 126, Issue 9, 1997, Pages 673-681

  Vadhan Raj, Saroj ^a   Murray, Lesley J ^b   Bueso Ramos, Carlos ^a   Patel, Shreyaskumar ^a   Reddy, Saraswati P ^a   Hoots, William K ^a   Johnston, Taren ^a   Papadopoulous, Nicholas E ^a   Hittelman, Walter N ^a   Johnston, Dennis A ^a   Yang, Timothy A ^c   Paton, Virginia E ^c   Cohen, Robert L ^c   Hellmann, Susan D ^c   Benjamin, Robert S ^a   Broxmeyer, Hal E ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c GENENTECH INC   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT THROMBOPOIETIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HEMATOPOIESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEGAKARYOCYTE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0030966361     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-9-199705010-00001     Document Type: Article

References (41)

1. Surgenor DM, Wallace EL, Hao SH, Chapman RH. Collection and transfusion of blood in the United States, 1982-1988. N Engl J Med. 1990;322: 1646-51.
2. Wallace EL, Churchill WH, Surgenor DM, An J, Cho G, McGurk S, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion. 1995;35:802-12.
3. Heyman MR, Schiffer CA. Platelet transfusion therapy for the cancer patient. Semin Oncol. 1990;17:198-209.
4. de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the C-Mpl ligand. Nature. 1994;369:533-8.
5. Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, Martin F, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell. 1994;77:1117-24.
6. Lok S, Kaushansky K, Holly RD, Kuijper JL, Lofton-Day CE, Oort PJ, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 1994;369:565-8.
7. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994;369:568-71.
8. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeaux M, et al. cMpl is a humoral regulator of megakaryocytopoiesis. Nature. 1994; 369:571-4.
9. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86:419-31.
10. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood. 1995;86:54-9.
11. Thomas GR, Thibodeaux H, Errett CJ, Mathias J, Marian M, Meng G, et al. In vivo biological effects of various forms of thrombopoietin in a murine model of transient pancytopenia. Stem Cells. 1996,1(Suppl 1):246-55.
12. Emmons RV, Reid DM, Cohen RL, Meng G, Young NS, Dunbar CE, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068-71.
13. Vadhan-Raj S, Broxmeyer HE, Andreeff M, Bandres JC, Buescher ES, Benjamin RS, et al. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood. 1995;86:2098-105.
14. Murray LJ, Mandich D, Bruno E, DiGiusto RK, Fu WC, Sutherland DR, et al. Fetal bone marrow CD34+CD41+ cells are enriched for multipotent hematopoietic progenitors, but not for pluripotent stem cells. Exp Hematol. 1996;24:236-45.
15. Broxmeyer HE, Cooper S, Vadhan-Raj S. Cell cycle status of erythroid (BFU-E), progenitor cells from the bone marrows of patients on a clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor. Exp Hematol. 1989;17:455-9.
16. Bruno E, Briddell R, Hoffman R. Effect of recombinant and purified hematopoietic growth factors on human megakaryocyte colony formation. Exp Hematol. 1988;16:371-7.
17. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188-93.
18. Rodak BF, ed. Diagnostic Hematology. Philadelphia: WB Saunders; 1995: 554-8.
19. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995;86:2442-848.
20. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-8.
21. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med. 1991;325:164-70.
22. Vose JM, Bierman PJ, Kessinger A, Coccia PF, Anderson J, Oldham FB, et al. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 1991;7:139-43.
23. American Society of Clinical Oncology, Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol. 1994;12:2471-508.
24. Smith JW 2d, Longo DL, Alvord WG, Janik JE, Sharfman WH, Gause BL, et al. The effects of treatment with interleukin-1α on platelet recovery after high-dose carboplatin. N Engl J Med. 1993;328:756-61.
25. Vadhan-Raj S, Kudelka AP, Garrison L, Gano J, Edwards CL, Freedman RS, et al. Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol. 1994;12:707-14.
26. Biesma B, Willemse PH, Mulder NH, Sleijfer DT, Gietma JA, Mull R, et al. Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood. 1992;80:1141-8.
27. Veldhuis GJ, Willemse PH, Sleijfer DT, van der Graaf WT, Groen HJ, Limburg PC, et al. Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol. 1995;13:2585-93.
28. Vadhan-Raj S, Papadopoulos NE, Burgess MA, Linke KA, Patel SR, Hays C, et al. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol. 1994;12:715-24.
29. Tepler I, Elias L, Smith JW 2d, Hussein M, Rosen G, Chang AY, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 1996;87:3607-14.
30. Keleman E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythemic sera. Acta Haematol (Basel). 1958;20:350-5.
31. Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood. 1996;87:2154-61.
32. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor expands the circulating haemopoietic circulating haemopoietic progenitor cell compartments in man. Lancet. 1988;1194-8.
33. Shea TC, Mason JR, Storniolo AM, Newton B, Breslin M, Mullen M, et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol. 1992;10:464-73.
34. Bensinger W, Singer J, Appelbaum F, Lilleby K, Longin K, Rowley S, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood. 1993;81:3158-63.
35. Murray LJ, Luen KM, Bruno E, Estrada MF, Cohen RL, Hellman SD, et al. Effects of thrombopoietin on megakaryocytes and progenitor cell population in bone marrow and peripheral blood of sarcoma patients [Abstract]. Blood. 1996;88(Suppl 1-2):351a.
36. Vadhan-Raj S, Patel S, Broxmeyer HE, Bueso-Ramos C, Reddy SP, Papadopolous N, et al. Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide [Abstract]. Blood. 1996; 88(Suppl 1-2):448a.
37. Fanucchi M, Glaspy J, Crawford J, Garst J, Figlin R, Sheridan W, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med. 1997;336:404-9.
38. Levin J. Thrombopoietin - clinically realized? [Editorial] N Engl J Med. 1997; 336:434-6.
39. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol. 1992;10:1266-77.
40. Neidhart JA, Mangalik A, Stidley CA, Tebich SL, Sarmiento LE, Pfile JE, et al. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. J Clin Oncol. 1992;10:1460-9.
41. Crawford J, Kreisman H, Garewal H, Jones S, Shoemaker D, Pupa MR, et al. A pharmacodynamic investigation of recombinant human granulocyte colony stimulating factor (r-metHuG-CSF) schedule variation in patients with small cell lung cancer (SCLC) given CAE chemotherapy [Abstract]. Proceedings of the American Society of Clinical Oncology. 1992;11:299.